A new strategy for metachronous XXXX : stereotactic body radiation therapy with concurrent chemotherapy.

@entity1 @entity2 @entity5 @entity5474
BACKGROUND/AIM: @entity1 with @entity2 often develop a @entity5474 after treatment of the initial @entity5 . In those cases, it is difficult to distinguish @entity2 ( @entity2 ) from lung metastasis. Therefore, both local therapy for a single lung lesions and systemic therapy for micrometastases are needed. This retrospective study aimed to evaluate the safety and tolerability of concurrent stereotactic body radiation therapy (SBRT) and chemotherapy in @entity1 with metachronous @entity2 . @entity1 AND METHODS: We reviewed the records of 10 @entity1 with metachronous @entity2 treated with SBRT and concurrent chemotherapy with curative intent from 2007 to 2013. The delivered radiation dose was 48 Gy in four fractions. RESULTS: All @entity1 received SBRT with concurrent chemotherapy on schedule. Complete response rate was 90%. Safety profile of this treatment was compatible with that of traditional chemoradiotherapy. CONCLUSION: Our study showed good feasibility and safety for SBRT with concurrent chemoradiotherapy.
